Prostate Cancer Staging and Survival Rates
The 2017 TNM classification (8th edition) is the current standard for prostate cancer staging, with 5-year survival rates of 100% for localized disease, approximately 100% for regional disease, and 32.3% for distant metastatic disease based on the most recent U.S. data. 1, 2, 3
TNM Staging Classification
The staging system is based on the 2017 Union for International Cancer Control (UICC) 8th edition 1:
T Stage (Primary Tumor - based on digital rectal examination)
- T1: Clinically inapparent tumor (not palpable or visible by imaging)
- T2: Tumor confined within prostate
- T2a: Involves ≤50% of one lobe
- T2b: Involves >50% of one lobe
- T2c: Involves both lobes
- T3: Tumor extends through prostatic capsule
- T3a: Extracapsular extension
- T3b: Invades seminal vesicle(s)
- T4: Tumor invades adjacent structures (bladder neck, external sphincter, rectum, levator muscles, pelvic wall)
N Stage (Regional Lymph Nodes)
- N0: No regional lymph node metastasis
- N1: Regional lymph node metastasis
M Stage (Distant Metastasis)
- M0: No distant metastasis
- M1a: Non-regional lymph node(s)
- M1b: Bone metastasis
- M1c: Other site(s) with or without bone disease
5-Year Survival Rates
Based on the most recent comprehensive U.S. data from 2011-2016 3:
By Stage
- Localized disease: 100% (10-year survival also 100%)
- Regional disease: Near 100%
- Distant metastatic disease: 32.3% overall (improved from 28.7% in 2001-2005)
Metastatic Disease Survival by Specific M Stage 4
For patients treated with primary androgen deprivation therapy:
- N1M0 (lymph node only): 76.0% 5-year overall survival
- M1a (non-regional lymph nodes): 57.5% 5-year overall survival
- M1b (bone metastasis): 54.0% 5-year overall survival
- M1c (distant metastasis): 40.0% 5-year overall survival
Important Clinical Considerations
The overall 5-year relative survival for all stages combined is 97% 2, reflecting the predominance of localized disease at diagnosis and the effectiveness of early detection and treatment.
Stage Distribution at Diagnosis 3
- Localized: 77%
- Regional: 11%
- Distant: 5%
- Unknown: 7%
Critical Caveats
Imaging-based staging (particularly PSMA PET/CT) is causing a stage shift 1. The recently proposed molecular imaging TNM (miTNM) classification using PSMA PET/CT is more sensitive than conventional staging, and patients staged with these advanced imaging modalities likely have better prognosis than their traditional TNM counterparts because of earlier detection within each stage category.
Racial disparities exist significantly 2, 3. Five-year survival for distant disease varies by race/ethnicity:
- Asian/Pacific Islanders: 42.0%
- Hispanics: 37.2%
- American Indian/Alaska Natives: 32.2%
- Black men: 31.6%
- White men: 29.1%
Black men have 67% higher incidence than White men and face worse outcomes despite similar stage at diagnosis, highlighting the need for consideration of race-specific factors in prognostication and treatment planning 2.
The TNM classification should be integrated with PSA level and Gleason grade for accurate prognostication, as clinical stage alone has limited independent predictive value when these other factors are considered 5.